Trial Profile

A Phase I Open-Label, Single-Centre Study to Assess the Concentration of AAI101 and Cefepime in Epithelial Lining Fluid and Plasma in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cefepime/enmetazobactam-Allecra-Therapeutics (Primary)
Indications Gram-negative infections; Urinary tract infections
Focus Pharmacokinetics
Sponsors Allecra Therapeutics

Most Recent Events

19 Oct 2020 Results assessing intrapulmonary pharmacokinetics of a regimen of cefepime-enmetazobactam, published in the Antimicrobial Agents and Chemotherapy.
13 Jul 2020 Status changed from recruiting to completed.
16 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com